

# Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study

Shan Chong,<sup>1-4,\*</sup> Peng Zhao,<sup>1-4,\*</sup> Rui-Bin Huang,<sup>5,\*</sup> Hu Zhou,<sup>6,\*</sup> Jia-Ning Zhang,<sup>7</sup> Ming Hou,<sup>8</sup> Yi Liu,<sup>9</sup> Hong-Xia Yao,<sup>10</sup> Ting Niu,<sup>11</sup> Jun Peng,<sup>8</sup> Ming Jiang,<sup>12</sup> Yan-Qiu Han,<sup>13</sup> Jian-Da Hu,<sup>14</sup> Ze-Ping Zhou,<sup>15</sup> Lin Qiu,<sup>16</sup> Lian-Sheng Zhang,<sup>17</sup> Xin Wang,<sup>18</sup> Hua-Quan Wang,<sup>19</sup> Ru Feng,<sup>20</sup> Lin-Hua Yang,<sup>21</sup> Liang-Ming Ma,<sup>22</sup> Shun-Qing Wang,<sup>23</sup> Pei-Yan Kong,<sup>24</sup> Wen-Sheng Wang,<sup>25</sup> Hui-Ping Sun,<sup>26</sup> Jing Sun,<sup>27</sup> He-Bing Zhou,<sup>28</sup> Tie-Nan Zhu,<sup>29</sup> Li-Ru Wang,<sup>30</sup> Jing-Yu Zhang,<sup>31</sup> Qiu-Sha Huang,<sup>1,4</sup> Hai-Xia Fu,<sup>1-4</sup> Ye-Jun Wu,<sup>1-4</sup> Yue-Ying Li,<sup>32</sup> Qian-Fei Wang,<sup>32</sup> Qian Jiang,<sup>1-4</sup> Hao Jiang,<sup>1-4</sup> Jin Lu,<sup>1-4</sup> Xiao-Jun Huang,<sup>1-4</sup> and Xiao-Hui Zhang<sup>1-4</sup>

<sup>1</sup>Peking University People's Hospital, Peking University Institute of Hematology, Beijing, China; <sup>2</sup>National Clinical Research Center for Hematologic Disease, Beijing, China; <sup>3</sup>Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China; <sup>4</sup>Collaborative Innovation Center of Hematology, Peking University, Beijing, China; <sup>5</sup>Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, China; <sup>6</sup>Department of Hematology, Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China; <sup>7</sup>Peking University Cancer Hospital and Institute, Beijing, China; <sup>8</sup>Department of Hematology, Qilu Hospital, Shandong University, Jinan, China; <sup>9</sup>Department of Geriatric Hematology, Chinese People's Liberation Army General Hospital, Beijing, China; <sup>10</sup>Department of Hematology, Hainan General Hospital, Haikou, China; <sup>11</sup>Department of Hematology, West China Hospital, Sichuan University, Chengdu, China; <sup>12</sup>Department of Hematology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, China; <sup>13</sup>Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China; <sup>14</sup>Fujian Institute of Hematology, Fujian Medical University Union Hospital, Fuzhou, China; <sup>15</sup>Department of Hematology, The Second Affiliated Hospital of Kunming Medical University, Kunming, China; <sup>16</sup>Department of Hematology, The First Hospital of Jilin University, Changchun, China; <sup>17</sup>Department of Hematology, Lanzhou University Second Hospital, Lanzhou, China; <sup>18</sup>Department of Hematology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, China; <sup>19</sup>Department of Hematology, Tianjin Medical University General Hospital, Tianjin, China; <sup>20</sup>Department of Hematology, Beijing Hospital, Ministry of Health, Beijing, China; <sup>21</sup>Department of Hematology, Second Affiliated Hospital of Shanxi Medical University, Taiyuan, China; <sup>22</sup>Department of Hematology, Affiliated Shanxi Big Hospital of Shanxi Medical University, Taiyuan, China; <sup>23</sup>Department of Hematology, Guangzhou First People's Hospital, Guangzhou, China; <sup>24</sup>Xinqiao Hospital, The Third Military Medical University, Chongqing, China; <sup>25</sup>Department of Hematology, Peking University First Hospital, Beijing, China; <sup>26</sup>Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; <sup>27</sup>Nanfang Hospital, Nanfang Medical University, Guangzhou, China; <sup>28</sup>Beijing Luhe Hospital, Capital Medical University, Beijing, China; <sup>29</sup>Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; <sup>30</sup>Fuxing Hospital, Capital Medical University, Beijing, China; <sup>31</sup>Department of Hematology, Second Hospital of Hebei Medical University, Shijiazhuang, China; and <sup>32</sup>Key Laboratory of Genomic and Precision Medicine, Collaborative Innovation Center of Genetics and Development, Beijing Institute of Genomics, Chinese Academy of Sciences, Beijing, China

## Key Points

- Intraparenchymal hemorrhage, platelet count, serious infections, severe bleeding events, and Glasgow coma scale predict poor prognosis.
- A prognostic model was developed and validated, and an application was established.

Intracranial hemorrhage (ICH) is a rare and life-threatening hemorrhagic event in patients with immune thrombocytopenia (ITP). However, its mortality and related risk factors remain unclear. Herein, we conducted a nationwide multicenter real-world study of ICH in adult ITP patients. According to data from 27 centers in China from 2005 to 2020, the mortality rate from ICH was 33.80% (48/142) in ITP adults. We identified risk factors by logistic univariate and multivariate logistic regression for 30-day mortality in a training cohort of 107 patients as follows: intraparenchymal hemorrhage (IPH), platelet count  $\leq 10 \times 10^9/L$  at ICH, a combination of serious infections, grade of preceding bleeding events, and Glasgow coma scale (GCS) level on admission. Accordingly, a prognostic model of 30-day mortality was developed based on the regression equation. Then, we evaluated the performance of the prognostic model through a bootstrap procedure for internal validation. Furthermore, an external validation with data from a test cohort with 35 patients from 11 other centers was conducted. The areas under the receiver operating characteristic (ROC) curves for the internal and external validation were 0.954 (95% confidence interval [CI], 0.910-0.998) and 0.942 (95% CI, 0.871-1.014),

Submitted 2 February 2022; accepted 24 May 2022; prepublished online on *Blood Advances* First Edition 9 June 2022; final version published online 25 July 2022. DOI 10.1182/bloodadvances.2022007226.

\*S.C., P.Z., R.-B.H., and H.Z. contributed equally to this study.

Data from this study can be obtained by sending an e-mail to the corresponding authors (zhangxh@bjmu.edu.cn or xjhrm@medmail.com.cn). Some of the data from this study have been used to identify risk factors of ICH in ITP patients. The results

have been published in: Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age. *Platelets* 2021;32(5): 633-641. doi: 10.1080/09537104.2020.1786042.

The full-text version of this article contains a data supplement.

© 2022 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.

respectively. Both calibration plots illustrated a high degree of consistency in the estimated and observed risk. In addition, the decision curve analysis showed a considerable net benefit for patients. Thus, an application (47.94.162.105:8080/ich/) was established for users to predict 30-day mortality when ICH occurred in adult patients with ITP.

## Introduction

Immune thrombocytopenia (ITP) is an acquired isolated thrombocytopenia with a platelet count of  $<100 \times 10^9/L$ , characterized by platelet destruction and impaired platelet production.<sup>1-4</sup> ITP can occur in all age ranges, with an incidence of 3.9 to 6.1 per 1 000 000 people every year, with 2 peaks, one during childhood and one at  $>60$  years of age.<sup>5,6</sup> Compared with the short-term and self-limited disease courses in children, ITP is more likely to be persistent or chronic in adults due to different pathogenesises.<sup>1,7</sup>

Bleeding has been considered one of the important clinical outcomes for ITP patients.<sup>8</sup> Although the mortality rate of ITP is only slightly higher than that of the general population, severe hemorrhagic events such as intracranial hemorrhage (ICH) are often considered to be associated with a poor prognosis.<sup>9-12</sup> According to previous reports, ICH occurs in approximately 1% of ITP patients with a mortality of 24.0% to 31.2%.<sup>9,13-15</sup> Lower platelet count, prior bleeding events, and antecedent head trauma have been shown to be associated with the development of ICH in pediatric and adult patients.<sup>13-17</sup> Meanwhile, prior hemorrhagic events and newly diagnosed ITP were related to death in a cohort of 40 children.<sup>14</sup> However, to date, risk factors for death from ICH in adults with ITP remain unclear.

We conducted a nationwide multicenter real-world study to identify risk factors for death within 30 days following ICH in ITP patients. To the best of our knowledge, this is the largest cohort of ICH in ITP to date. Furthermore, we developed and validated a prognostic model. An application was established to predict the outcome of ICH in adult patients with ITP.

## Methods

### Patient selection and study design

We conducted a nationwide, multicenter, real-world study to collect data from patients with ITP who experienced ICH between 2005 and 2020. A total of 27 representative hospitals participated in this study, with a training cohort from 16 centers and a test cohort from another 11 centers. The specific list of centers is summarized in supplemental Table 1. We took full account of the geographical diversity when dividing the study population. The specific inclusion criteria were as follows: 1) age  $>18$  years old; 2) a diagnosis of primary ITP; and 3) ICH occurring after the diagnosis of ITP. Patients newly diagnosed with ITP at the onset of ICH were excluded. All patients included in our study had a follow-up period of  $\geq 30$  days following ICH. For each patient experiencing ICH enrolled, a control case from the same center matched for time to ITP diagnosis ( $\pm 1$  year) and ITP duration ( $\pm 180$  days) was selected. Data including demographic information, comorbidities, disease characteristics for ITP, antecedent events, and clinical features of ICH were recorded in detail. To ensure accuracy, relevant information of each

individual was extracted from the electronic medical record system and checked by another researcher independently.

This study was conducted in strict accordance with the Declaration of Helsinki and was approved by ethics committees or central institutional review boards of the Peking University People's Hospital and all other hospitals involved.

### Definitions and evaluations

Diagnoses for primary ITP were identified based on the current international criteria.<sup>3,18-20</sup> Secondary ITP patients were not included in our study.<sup>14,16</sup> According to the duration of ITP, disease courses were divided into newly diagnosed ( $<3$  months), persistent (3 to 12 months), and chronic ( $>12$  months).<sup>3,20</sup> The severity of hemorrhagic events before ICH was graded by the extent of involvement: mild (skin manifestations or no bleeding), moderate (visible mucosal bleeding), and severe (organ or internal mucosal bleeding).<sup>16,21</sup> A life-threatening bleeding event could be diagnosed with hemorrhagic shock or hemoglobin loss  $>2$  g/dL within 1 day.<sup>16</sup>

ICH refers to any hemorrhage involving the intracranial vault, including intraparenchymal (IPH), subarachnoid (SAH), subdural, and epidural locations.<sup>22,23</sup> The diagnosis of ICH was based on imaging evidence from computed tomography or magnetic resonance imaging. Impairment of consciousness on admission was evaluated by the Glasgow Coma Scale (GCS): mild (13 to 14), moderate (9 to 12), or severe (3 to 8).<sup>24</sup> Previous infections referred to infections occurring 1 month before ICH or at the last follow-up. Serious infections refer to those requiring IV infusion of antibacterial, antifungal, or antiviral drugs for treatment, ranging from grade  $\geq 3$  according to the Common Terminology Criteria for Adverse Events grading scale (version 5.0).<sup>25</sup> In our study, hypertension referred to systolic blood pressure  $\geq 160$  mm Hg and/or diastolic blood pressure  $\geq 100$  mm Hg of hypertension grade  $\geq 2$ .<sup>26</sup> The diagnostic criteria for diabetes mellitus were fasting blood glucose  $\geq 7.0$  mmol/L or glycated hemoglobin  $\geq 6.5\%$ .<sup>27</sup> Impaired renal function referred to a serum creatinine  $\geq 200$   $\mu\text{mol/L}$ , undergoing long-term dialysis, or a history of renal transplantation.<sup>15</sup> A platelet count  $<30 \times 10^9/L$  after 28 days of treatment was considered glucocorticoid resistance.<sup>28</sup>

### Statistical analysis

In our study, the distribution of categorical variables was recorded in counts (proportions), which were compared by Pearson's  $\chi^2$  test and Fisher's exact test. Continuous variables were expressed as the median (interquartile range) and were compared by the Mann-Whitney  $U$  test. Statistically significant differences were defined as  $P < 0.05$  (2-sided). We conducted logistic regression analysis with Firth's penalized likelihood to select variables included in the prognostic model. Thus, the prognostic model was developed using backward stepwise logistic regression according to the Akaike information criterion. Internal validation of the model was performed by repeating the bootstrap method 1000 times for the training cohort. Furthermore, the test cohort from geographically independent

centers was used to implement the external validation. The predictive value of this prognostic model was assessed by its discriminative power (via area under the curve [AUC]), calibration power (via calibration plots), and net benefit (via decision curve analysis). All of the above statistical work was calculated using SAS 9.4 for Windows and R software 4.0.3.

## Results

### Baseline characteristics

In total, 142 adult ITP patients with ICH were enrolled in our study. All ICHs were symptomatic; in other words, there was no subclinical ICH detected incidentally by magnetic resonance imaging. We summarized the clinical features of the patients in Table 1 and compared the differences between the training and test cohorts. Among patients with ICH, the median age was 53 years (interquartile range, 35 to 64 years), and 33.80% (48/142) of patients died within 30 days. There were no significant differences in sex, age, comorbidities, platelet count at ITP diagnosis, ITP duration, previous treatments, or events before ICH in the training and test cohorts. The 30-day mortality rates for the training and test cohorts were 36.45% (39/107) and 25.71% (9/35), respectively, with no significant difference ( $P = 0.244$ ). In addition, 142 control cases of ITP adults without ICH were also enrolled in our study. The baseline clinical features are summarized in supplemental Table 2.

### Clinical features of ICH

The median platelet count at the occurrence of ICH was  $7 \times 10^9/L$  in our study cohort. Among them, 65.7% (90/142) of patients had platelet counts of  $10 \times 10^9/L$  or less when ICH occurred.

In our study, 129 patients had specific bleeding site records. Among them, bleeding events in 29 patients occurred in  $>1$  intracranial site. The parenchyma was the most commonly affected area (58.14% [75/129]). In addition, the percentages of patients suffering from SAH, subdural, and epidural were 23.26% (30/129), 21.71% (28/129), and 2.33% (3/129), respectively. A total of 44.3% of our study cohort (63/142) had an abnormal GCS score on admission. A total of 14.79% (21/142) of patients had combined serious infections. A total of 71.43% (15/21) of them were treated with glucocorticoids, and 14.28% (3/21) were on rituximab. The detailed clinical features at ICH in the training and test cohorts are listed in Table 1.

### Risk factors for developing ICH

We depicted the receiver operating characteristic (ROC) curve to determine the association between platelet count at ITP diagnosis and ICH. As shown in supplemental Figure 1, the baseline platelet count was significantly associated with the occurrence of ICH in adult patients with ITP ( $P < 0.001$ ; AUC = 0.702; 95% CI, 0.641-0.763). Accordingly, a platelet count  $\leq 10 \times 10^9/L$  at initial diagnosis was identified as the optimal discriminant threshold of a higher ICH risk with a Youden index of 0.338.

Furthermore, we conducted a logistic regression analysis to identify other risk factors for developing ICH. According to the univariate and multivariate analyses, platelet count  $\leq 10 \times 10^9/L$ , preceding severe bleeding events, head trauma, or surgery were independent factors for adult ITP patients developing ICH.

### Variable selections for the prognostic model

In total, 107 patients were included in the training cohort. We performed a univariate logistic regression analysis to identify potential predictors to include in the prognostic model. IPH, SAH, platelet count at ICH  $\leq 10 \times 10^9/L$ , GCS score on admission, a combination of serious infections, grade of preceding bleeding events, and absence of head trauma were selected as potential predictors of 30-day mortality of ICH with a  $P < 0.10$  (Table 2).

### Development of the prognostic model

Multivariate logistic regression analysis was performed in the training cohort. Nine patients were missing data about the specific locations of ICH, and thus, 96 patients were ultimately included to develop the prognostic model. As shown in Table 2, IPH ( $P = 0.001$ ), platelet count at ICH  $\leq 10 \times 10^9/L$  ( $P = 0.045$ ), preceding severe bleeding events ( $P = 0.014$ ), GCS between 9 and 12 ( $P = 0.016$ ), and GCS  $\leq 8$  ( $P = 0.04$ ) were proven to be independent risk factors for 30-day mortality of ICH. In addition, although statistically nonsignificant ( $P = 0.083$ ), combined serious infections might also affect the 30-day prognosis of patients in clinical practice and were also included in the prognostic model. The coefficients of each factor in the 30-day mortality prediction model were recorded as the  $\beta$ -value of the regression equation.

Furthermore, to demonstrate the applicability of our prognostic model among different ages, we conducted a multivariate analysis adjusted for age. As shown in supplemental Table 4, the risk factors involved in the prognostic model were all related to the 30-day outcomes of patients of different ages.

### Internal validation of the prognostic model

We carried out internal validation by 1000 bootstrap replicates in the training cohort. Accordingly, we plotted a ROC curve (Figure 1A). The AUC was 0.954 (95% CI, 0.910-0.998), which illustrated the good discrimination power for predicting 30-day mortality of ICH in adult patients with ITP. Meanwhile, the calibration plot demonstrated high consistency between the estimated and actual risks of 1-month death (Figure 2A), which further demonstrated the prognostic efficacy of this model. Moreover, we generated a decision curve analysis curve to determine whether the model could provide clinical benefit for ITP patients suffering from ICH. As shown in Figure 3A, the prognostic model contributed to considerable net benefits.

### External validation of the prognostic model

To further evaluate the predictive power of our prognostic model, we performed independent external validation with a test cohort from 11 other geographically independent centers. Four patients were missing data on the ICH type, so 31 cases were used for the external validation process. As shown in Figure 1B, the AUC of the ROC curve in the test cohort was 0.942 (95% CI, 0.871-1.014), which further proved the discrimination power of the prognostic model. The calibration efficacy was further illustrated as a highly consistent calibration plot in the test cohort (Figure 2B). Moreover, patients in the test cohort also attained net clinical benefits from this prognostic model (Figure 3B).

**Table 1. Clinical Characters of ITP Patients with ICH**

	Total	Training Cohort	Test Cohort	P
Patients, n	142	107	35	
30-d mortality	48 (33.803)	39 (36.449)	9 (25.714)	.244
<b>Demographic features</b>				
Male, n (%)	47 (33.099)	35 (32.710)	12 (34.286)	.863
Age (yr), median (IQR)	53 (35-64)	53 (35-65)	49 (29-59)	.475
<b>Comorbidity, n (%)</b>				
Hypertension	22 (15.603)	15 (14.019)	7 (20.588)	.358
Diabetes mellitus	16 (11.348)	15 (14.019)	1 (2.941)	.076
Impaired renal function	3 (2.128)	3 (2.804)	0	–
Alcohol use (>80 g/d)	2 (1.418)	2 (1.869)	0	–
Previous stroke	4 (2.817)	3 (2.804)	1 (2.857)	.987
Previous infections	16 (11.268)	10 (9.346)	6 (17.143)	.205
Serious infections	21 (14.789)	15 (14.019)	6 (17.143)	.651
<b>Clinical features related to ITP</b>				
Platelet count at ITP diagnosis $\times 10^9/L$ , median (IQR)	9 (4-20)	9 (4-20)	9 (5-20)	.848
ITP duration	–	–	–	.684
Within 3 mo, n (%)	33 (23.239)	23 (21.495)	10 (28.571)	–
3-12 mo, n (%)	14 (9.859)	11 (10.280)	3 (8.571)	–
>12 mo, n (%)	95 (66.901)	73 (68.224)	22 (62.857)	–
Previous treatment, n (%)				
No treatment received	30 (21.127)	25 (23.364)	5 (14.286)	.253
Glucocorticoid resistance, n (%)	44 (31.206)	33 (31.132)	11 (31.429)	.974
<b>Events before ICH, n (%)</b>				
Head trauma or surgery	12 (8.451)	10 (9.346)	2 (5.714)	.503
Medications interfering with hemostasis	12 (8.451)	11 (10.280)	1 (2.857)	.171
Anticoagulant and antiplatelet drugs	8 (5.634)	8 (7.477)	0	–
NSAIDs	6 (4.225)	5 (4.673)	1 (2.857)	.643
Preceding bleeding events*	120 (84.507)	89 (83.178)	31 (88.571)	.444
Time interval to ICH, mo	1 (0,2)	1 (0,3)	1 (0,2)	.211
Severity of bleeding	–	–	–	.917
Mild (skin manifestations or no bleeding)	54 (38.028)	40 (37.383)	14 (40.000)	–
Moderate (visible mucosal bleeding)	31 (21.831)	23 (21.495)	8 (22.857)	–
Severe (organ or internal mucosal bleeding)	57 (40.141)	44 (41.121)	13 (37.143)	–
Life-threatening bleeding events	22 (15.493)	15 (14.019)	7 (20.000)	.396
<b>Clinical features for ICH</b>				
Platelet count at ICH $\times 10^9/L$ , median (IQR)	7 (2-20)	7 (3-15)	6 (1-23)	.558
Type of ICH, n (%)*				
IPH	75 (58.140)	57 (59.375)	18 (54.545)	.628
SAH	30 (23.256)	24 (25.000)	6 (18.182)	.424
SDH	28 (21.705)	21 (21.875)	7 (21.212)	.936
EDH	3 (2.326)	3 (3.125)	0	–
GCS on admission, n (%)	–	–	–	.918
15	79 (55.634)	59 (55.140)	20 (57.143)	–
13-14	27 (19.014)	21 (19.626)	6 (17.143)	–
9-12	25 (17.606)	18 (16.822)	7 (20.000)	–
$\leq 8$	11 (7.746)	9 (8.411)	2 (5.714)	–

EDH, epidural hemorrhage; GCS, Glasgow Coma Scale; IQR, interquartile range; NSAIDs, nonsteroidal antiinflammatory drugs; SDH, subdural hemorrhage.  
 \*Thirteen patients missed detailed records of ICH location: 9 patients were in the training cohort, and 4 patients were in the test cohort.

**Table 2. Predictors for 30-Day Mortality of ICH in Adult Patients with ITP in the Training Cohort**

Variables	Univariate			Multivariate			
	OR	95% CI	P	OR	95% CI	P	β
Age ≥70, yr	2.586	(0.923-7.244)	.071	1.122	(0.145-8.683)	.912	–
Sex	0.957	(0.414-2.210)	.917	–	–	–	–
Platelet count at ITP diagnosis ≤10 × 10 <sup>9</sup> /L	2.057	(0.895-4.727)	.089	2.903	(0.427-19.762)	.276	2.586
Platelet count at ICH ≤10 × 10 <sup>9</sup> /L	7.778	(2.490-24.290)	<.001*	7.993	(1.052-60.733)	.045*	2.079
Hypertension	1.192	(0.390-3.644)	.758	–	–	–	–
Diabetes mellitus	0.592	(0.175-2.005)	.400	–	–	–	–
Previous infections	0.726	(0.177-2.986)	.657	–	–	–	–
Anticoagulants and antiplatelet agents	0.559	(0.107-2.912)	.489	–	–	–	–
NSAIDs	0.421	(0.045-3.907)	.447	–	–	–	–
Combination of serious infections	6.286	(1.842-21.452)	.003*	5.940	(0.791-44.587)	.083	1.782
Preceding head trauma or surgery	0.071	(0.003-1.421)	.084	0.531	(0.022-12.872)	.697	–
No treatment received	1.218	(0.486-3.055)	.674	–	–	–	–
Glucocorticoid resistance	1.248	(0.534-2.918)	.609	–	–	–	–
<b>Preceding bleeding grade</b>							
Mild	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	–
Moderate	2.479	(0.716-8.583)	.152	3.967	(0.358-43.947)	.261	1.378
Severe	8.185	(2.848-23.523)	<.001*	17.757	(1.790-176.180)	.014*	2.877
Bleeding event in the last month	1.443	(0.652-3.191)	.366	–	–	–	–
<b>Type of ICH</b>							
IPH	19.161	(4.213-87.141)	<.001*	37.029	(4.529-302.773)	.001*	3.612
SAH	0.224	(0.061-0.823)	.024*	0.844	(0.120-5.940)	.865	–
SDH	0.418	(0.128-1.371)	.150	–	–	–	–
<b>GCS on admission</b>							
15	Ref.	Ref.	Ref.	Ref.	Ref.	Ref.	–
13-14	5.051	(1.661-15.359)	.004*	2.928	(0.445-19.249)	.264	1.074
9-12	11.111	(3.313-37.260)	<.001*	17.294	(1.687-177.256)	.016*	2.851
≤8	44.444	(4.941-399.773)	.001*	81.894	(4.195-1598.624)	.004*	4.406

GCS, Glasgow Coma Scale; NSAIDs, nonsteroidal antiinflammatory drugs; SDH, subdural hemorrhage.  
\*P < 0.05.

## Establishing an application based on the prognostic model


Based on the analysis above, we believe the prognostic model has the considerable predictive ability for 30-day mortality of ICH in ITP patients. Thus, we established an application (47.94.162.105:8080/ich/) based on this prognostic model (Figure 4). Users could log on to the website to predict patient outcomes when ICH occurred in adult patients with ITP.

## Discussion

ICH has been regarded as a severe and fatal complication in patients with ITP, the 30-day mortality of which is usually a clinical outcome of concern to physicians.<sup>8,9,29</sup> It has been demonstrated that ICH mortality was significantly higher in patients with coagulation disorders than in those without coagulation disorders.<sup>30</sup> However, probably due to its low incidence, no large-scale clinical studies have thus far confirmed the 30-day mortality and associated risk factors in adult ITP. We conducted a nationwide multicenter

real-world study with 142 samples to address this research gap. The mortality rate for patients with ICH was previously reported to be 25% to 52%, similar to the mortality rate of 33.8% for ITP patients in this study.<sup>31-33</sup> We identified 5 risk factors (IPH, platelet count ≤10 × 10<sup>9</sup>/L at ICH, a combination of serious infections, grade of preceding bleeding events, and GCS level on admission) associated with death. Accordingly, a prognostic model of 30-day mortality was developed and validated. Thus, we have developed an application in the form of a website where users can log in to predict the risk of death of ICH in ITP patients.

The platelet count in patients with ITP is always a concern. In our study, we identified an association between a low platelet count (≤10 × 10<sup>9</sup>/L) and the development and prognosis of ICH in adult ITP patients. The risk threshold was also consistent with previous reports of ICH or other major bleeding events.<sup>17,34-38</sup> Meanwhile, this finding has also been observed in patients with acute leukemia.<sup>39</sup> Previous experimental studies may provide a potential explanation for this risk threshold, reporting that platelets could maintain vascular hemostasis unless the platelet count was




**Figure 1. ROC curve of the prognostic model in the training and test cohorts.** (A) ROC curve of the prognostic model for the training. The area under the curve (AUC) was 0.954 (95% CI, 0.910-0.998). (B) ROC curve of the prognostic model for the test cohort. The AUC was 0.942 (95% CI, 0.871-1.014).

<7 to  $8 \times 10^9/L$ .<sup>40</sup> Therefore, it is important to recognize that for patients with severe ITP (platelet count  $\leq 10 \times 10^9/L$ ), intensive therapy should be adopted. This study found that patients with a previous serious bleeding event had a higher likelihood of developing ICH and an even worse prognosis. Platelet microparticles, vesicles derived from platelet membranes, were reported to be 50- to 100-fold more procoagulant than the surface of activated platelets and to be significantly higher in patients with ITP.<sup>41</sup> However, the concentrations of platelet microparticles are different in ITP patients with and without hemorrhage, which probably accounts for the risk and prognosis of bleeding.<sup>42</sup> To date, several scoring systems have been proposed to predict the future risk of bleeding in ITP patients.<sup>21,43,44</sup> Therefore, we believe that


more aggressive interventions are necessary for patients at higher risk of bleeding.

According to large-scale epidemiological surveys, the short-term mortality of IPH is 25% to 48%.<sup>45,46</sup> More importantly, thrombocytopenia might contribute to a progressive hemorrhage of IPH.<sup>47</sup> In fact, thrombocytopenia has also been found to be a predictor of a poor outcome in spontaneous IPH.<sup>48</sup>

In addition, there is a great deal of evidence that the GCS score could be an independent predictor of early death in patients with ICH.<sup>49</sup> As reported, a lower GCS score might indicate a worse ICH and a greater hemorrhage volume, which could explain the association with a poor prognosis.<sup>50,51</sup>



**Figure 2. Calibration plot of the prognostic model in the training and test cohorts.** (A) Calibration plot of the prognostic model for the training cohort. (B) Calibration plot of the prognostic model system for the test cohort. The x-axis plots the predicted 30-day mortality of ICH in adult patients with ITP; the y-axis plots the observed 30-day mortality in our study. A 45° diagonal line represents the ideal calibration plot.



**Figure 3. Decision curve analysis of the prognostic model in the training and test cohorts.** (A) Decision curve analysis of the prognostic model for the training cohort. (B) Decision curve analysis of the prognostic model for the test cohort. Black line: assuming no patient died within 30 days. Gray line: assuming all patients died within 30 days. These 2 lines served as references.

Infection complications were reported to occur in 20% to 31% of patients with ICH as a risk factor for a poor prognosis.<sup>52-55</sup> In fact, acute brain injury could lead to immunosuppression because of the dysregulation of brain-immune interactions, which accounts for the high incidence and poor prognosis of coinfection in ICH. Meanwhile, it has been noted that the use of glucocorticoids and rituximab in ITP patients exposes them to a higher risk of infection.<sup>56,57</sup> The high morbidity and mortality of pneumonia in ITP patients have also been demonstrated, as in

our previous study.<sup>58</sup> Evidence has also accumulated about the association between infections and coagulation dysfunction.<sup>59,60</sup> Thus, we speculated that ITP and infections might interact with each other. This reminded us again of the importance of combating infection in patients with ITP.

We found that cranial trauma was a risk factor for the development of ICH, consistent with previous conclusions.<sup>13,15,16</sup> However, we found no deaths in any patients (n = 12) with ICH secondary to prior

**Figure 4. An application (47.94.162.105:8080/ich/) to predict the 30-day mortality of intracranial hemorrhage (ICH) in ITP patients.** Users can visit the site and fill in these associated clinical features. After submission, the application can automatically output the patient's risk of death within 30 days following ICH in the form of a percentage.

trauma, which might suggest the severity of spontaneous ICH in patients with ITP.

Notably, older age ( $\geq 70$  years) was related to 30-day mortality of ICH according to the univariate analysis; although we did not find it to be an independent risk factor, which might be explained by the association between older age and IPH, a combination of serious infections, and GCS on admission.<sup>61-63</sup> Due to sample size limitations, we did not stratify patients to analyze the differences in risk factors for death among patients of different ages. In addition, the use of medications interfering with hemostasis was previously reported to affect the outcome of patients with ICH.<sup>64,65</sup> However, due to the thrombocytopenia of our study population, only 12 patients reported the use of medications interfering with hemostasis, so it was difficult to identify their impact on the prognosis of ICH.

Recent consensus recommended a combination of initial treatment (eg, steroids and IV immunoglobulin) and platelet transfusion as an emergency treatment for patients with active, significant bleeding. TPO-RA and other options should be considered, especially for patients without significant response to first-line therapy.<sup>18</sup> Thereby, an individualized assessment for disease severity and prognosis stratification may contribute to such therapeutic decision-making. For patients who have developed ICH, our model may provide useful information for therapeutic options according to the estimated risk of mortality, including special treatments, the timing of interventions, and the balance of treatment benefits and costs. Notably, 66.9% of patients developing ICH in this study suffered chronic ITP, indicating the significance of subsequent treatment options. The choice of second-line therapy, as highlighted by recent guidelines, should be individualized based on multiple factors, including the duration of ITP and the frequency of bleeding episodes requiring hospitalization or rescue medication.<sup>18</sup> Consistent with previous studies, our work found risk factors, including a platelet count  $< 10 \times 10^9/L$ , preceding hemorrhagic events, and head trauma, for the development of ICH.<sup>13-17,66</sup> More importantly, we identified that a low platelet count ( $< 10 \times 10^9/L$ ) and severe bleeding indicated a poor prognosis of ICH. These findings may assist with the refined management of chronic ITP. Patients with a high risk for ICH and those with higher estimated mortality once developing ICH might be considered for more intensive therapy (eg, a combination of thrombopoietin receptor agonists or rituximab with initial treatment and sometimes splenectomy<sup>18</sup>) to increase the platelet count.

Some limitations existed in this real-world study. First, due to the limitations of the retrospective nature of the study, some data were

missing. Meanwhile, there might be some recall bias in the reporting of hemorrhagic events before ICH. Occult bleeding, for instance, microscopic hematuria and cerebral microbleeds, have been reported to be frequent in severe ITP.<sup>66,67</sup> Therefore, the frequency and severity of antecedent hemorrhagic events were likely to be underestimated. In addition, we defined 30-day mortality as the primary outcome indicator, but other poor prognoses following ICH, including disability and neurological dysfunction, may also merit investigation. Additionally, despite having the largest population of ICH in ITP to date, our cohort sample was of a single nationality and still not large enough, which might affect the performance of the prognostic model. We expect that our prognostic model will be used in clinical practice, providing benefits to patients and further validating its predictive power.

## Acknowledgments

This work was supported by the National Key Research and Development Program of China (No. 2021YFC2500300), National Natural Science Foundation of China (No. 81970113), Key Program of National Natural Science Foundation of China (No. 81730004), and Capital Health Research and Development of Special (No. 2022-1-4082).

## Authorship

Contribution: X.-H.Z. and X.-J.H. designed the study; R.-B.H., H.Z., J.-N.Z., M.H., Y.L., H.-X.Y., T.N., J.P., M.J., Y.-Q.H., J.-D.H., Z.-P.Z., L.Q., L.-S.Z., X.W., H.-Q.W., R.F., L.-H.Y., L.-M.M., S.-Q.W., P.-Y.K., W.-S.W., H.-P.S., J.S., H.-B.Z., T.-N.Z., L.-R.W., and J.-Y.Z. collected and analyzed data; Q.-S.H., H.-X.F., Y.-J.W., Y.-Y.L., Q.-F.W., Q.J., H.J., and J.L. assisted in the research; S.C., P.Z., R.-B.H., and H.Z. wrote the manuscript; and all authors critically revised, reviewed, and approved the final version of this manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

ORCID profiles: T.N., 0000-0003-1580-1014; J.P., 0000-0003-1434-1490; X.W., 0000-0001-8051-1481.

Correspondence: Xiao-Hui Zhang, No. 11 Xizhimen South Street, Xicheng District, Beijing, China; e-mail: zhangxh@bjmu.edu.cn; Xiao-Jun Huang, No. 11 Xizhimen South Street, Xicheng District, Beijing, China; e-mail: xjhrm@medmail.com.cn.

## References

1. Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. *Blood*. 2017;129(21):2829-2835.
2. Rodeghiero F, Besalduch J, Michel M, Provan D, Grotzinger K, Thompson G. Treatment practices in adults with chronic immune thrombocytopenia - a European perspective. *Eur J Haematol*. 2010;84(2):160-168.
3. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. *Blood*. 2009;113(11):2386-2393.
4. Cooper N, Ghanima W. Immune thrombocytopenia. *N Engl J Med*. 2019;381(10):945-955.
5. Schoonen WM, Kucera G, Coalson J, et al. Epidemiology of immune thrombocytopenic purpura in the general practice research database. *Br J Haematol*. 2009;145(2):235-244.
6. Weycker D, Hanau A, Hatfield M, et al. Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis. *J Med Econ*. 2020;23(2):184-192.



7. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia [published correction appears in *Blood Adv*. 2020;4(2):52]. *Blood Adv*. 2019;3(23):3829-3866.
8. Neunert C, Noroozi N, Norman G, et al. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review. *J Thromb Haemost*. 2015;13(3):457-464.
9. Arnold DM. Bleeding complications in immune thrombocytopenia. *Hematology (Am Soc Hematol Educ Program)*. 2015;2015(1):237-242.
10. Nørgaard M, Jensen AØ, Engebjerg MC, et al. Long-term clinical outcomes of patients with primary chronic immune thrombocytopenia: a Danish population-based cohort study. *Blood*. 2011;117(13):3514-3520.
11. Frederiksen H, Maegbaek ML, Nørgaard M. Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study. *Br J Haematol*. 2014;166(2):260-267.
12. Adelborg K, Kristensen NR, Nørgaard M, et al. Cardiovascular and bleeding outcomes in a population-based cohort of patients with chronic immune thrombocytopenia. *J Thromb Haemost*. 2019;17(6):912-924.
13. Elalfy MS, Eltonbary KYEM, El Ghamry IR, et al. Intracranial hemorrhage in primary immune thrombocytopenia (ITP): 20 years' experience in pediatrics. *Eur J Pediatr*. 2021;180(5):1545-1552.
14. Psaila B, Petrovic A, Page LK, Menell J, Schonholz M, Bussel JB. Intracranial hemorrhage (ICH) in children with immune thrombocytopenia (ITP): study of 40 cases. *Blood*. 2009;114(23):4777-4783.
15. Zhao P, Hou M, Liu Y, et al. Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age. *Platelets*. 2021;32(5):633-641.
16. Melboucy-Belkhir S, Khellaf M, Augier A, et al. Risk factors associated with intracranial hemorrhage in adults with immune thrombocytopenia: a study of 27 cases. *Am J Hematol*. 2016;91(12):E499-E501.
17. Hato T, Shimada N, Kurata Y, et al. Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan. *Blood Adv*. 2020;4(8):1648-1655.
18. Provan D, Arnold DM, Bussel JB, et al. Updated international consensus report on the investigation and management of primary immune thrombocytopenia. *Blood Adv*. 2019;3(22):3780-3817.
19. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. *Blood*. 2011;117(16):4190-4207.
20. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. *Blood*. 2010;115(2):168-186.
21. Rodeghiero F, Michel M, Gernsheimer T, et al. Standardization of bleeding assessment in immune thrombocytopenia: report from the International Working Group. *Blood*. 2013;121(14):2596-2606.
22. Caceres JA, Goldstein JN. Intracranial hemorrhage. *Emerg Med Clin North Am*. 2012;30(3):771-794.
23. Freeman WD, Aguilar MI. Intracranial hemorrhage: diagnosis and management. *Neurol Clin*. 2012;30(1):211-240, ix.
24. Mehta R, Chinthapalli K. Glasgow coma scale explained. *BMJ*. 2019;365:l1296.
25. National Cancer Institute. *Common Terminology Criteria for Adverse Events*. Bethesda, MD: CTCAE; 2018.
26. Williams B, Mancia G, Spiering W, et al. 2018 Practice guidelines for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension [published correction appears in *Blood Press*. 2019;28(1):74]. *Blood Press*. 2018;27(6):314-340.
27. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2013;36(Suppl 1):S67-74.
28. Wei Y, Ji XB, Wang YW, et al. High-dose dexamethasone vs prednisone for treatment of adult immune thrombocytopenia: a prospective multicenter randomized trial. *Blood*. 2016;127(3):296-302, quiz 370.
29. Hemphill JC III, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. *Stroke*. 2001;32(4):891-897.
30. Kinnunen J, Satopää J, Niemelä M, Putaala J. Coagulopathy and its effect on treatment and mortality in patients with traumatic intracranial hemorrhage. *Acta Neurochir (Wien)*. 2021;163(5):1391-1401.
31. Broderick JP, Brott T, Tomsick T, Miller R, Huster G. Intracerebral hemorrhage more than twice as common as subarachnoid hemorrhage. *J Neurosurg*. 1993;78(2):188-191.
32. Sacco S, Marini C, Toni D, Olivieri L, Carolei A. Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. *Stroke*. 2009;40(2):394-399.
33. Mansouri B, Heidari K, Asadollahi S, Nazari M, Assarzagdegan F, Amini A. Mortality and functional disability after spontaneous intracranial hemorrhage: the predictive impact of overall admission factors. *Neurol Sci*. 2013;34(11):1933-1939.
34. Allard CB, Scarpelini S, Rhind SG, et al. Abnormal coagulation tests are associated with progression of traumatic intracranial hemorrhage. *J Trauma*. 2009;67(5):959-967.
35. Schnüriger B, Inaba K, Abdelsayed GA, et al. The impact of platelets on the progression of traumatic intracranial hemorrhage. *J Trauma*. 2010;68(4):881-885.
36. Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. *Semin Thromb Hemost*. 1977;3(3):160-174.
37. Neunert CE, Buchanan GR, Blanchette V, et al. Relationships among bleeding severity, health-related quality of life, and platelet count in children with immune thrombocytopenic purpura. *Pediatr Blood Cancer*. 2009;53(4):652-654.

38. Piel-Julian ML, Mahévas M, Germain J, et al; CARMEN investigators group. Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults. *J Thromb Haemost.* 2018;16(9):1830-1842.
39. Nixon S, Lieberman L, Atenafu EG, et al. Clinical outcomes and transfusion management following intracranial hemorrhage in patients with acute leukemia. *Transfusion.* 2020;60(2):269-274.
40. Hanson SR, Slichter SJ. Platelet kinetics in patients with bone marrow hypoplasia: evidence for a fixed platelet requirement. *Blood.* 1985;66(5):1105-1109.
41. Sinauridze EI, Kireev DA, Popenko NY, et al. Platelet microparticle membranes have 50- to 100-fold higher specific procoagulant activity than activated platelets. *Thromb Haemost.* 2007;97(3):425-434.
42. Jy W, Horstman LL, Arce M, Ahn YS. Clinical significance of platelet microparticles in autoimmune thrombocytopenias. *J Lab Clin Med.* 1992; 119(4):334-345.
43. Khellaf M, Michel M, Schaeffer A, Bierling P, Godeau B. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. *Haematologica.* 2005;90(6):829-832.
44. Page LK, Psaila B, Provan D, et al. The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. *Br J Haematol.* 2007;138(2):245-248.
45. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. *Lancet Neurol.* 2010;9(2):167-176.
46. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. *Lancet Neurol.* 2009;8(4):355-369.
47. Yuan F, Ding J, Chen H, et al. Predicting progressive hemorrhagic injury after traumatic brain injury: derivation and validation of a risk score based on admission characteristics. *J Neurotrauma.* 2012;29(12):2137-2142.
48. Fang HY, Lin CY, Ko WJ. Hematology and coagulation parameters predict outcome in Taiwanese patients with spontaneous intracerebral hemorrhage. *Eur J Neurol.* 2005;12(3):226-232.
49. Balami JS, Buchan AM. Complications of intracerebral haemorrhage. *Lancet Neurol.* 2012;11(1):101-118.
50. Muschelli J, Ullman NL, Sweeney EM, et al. Quantitative intracerebral hemorrhage localization. *Stroke.* 2015;46(11):3270-3273.
51. Kumral E, Kocaer T, Ertübey NO, Kumral K. Thalamic hemorrhage. A prospective study of 100 patients. *Stroke.* 1995;26(6):964-970.
52. Lord AS, Langefeld CD, Sekar P, et al. Infection after intracerebral hemorrhage: risk factors and association with outcomes in the ethnic/racial variations of intracerebral hemorrhage study. *Stroke.* 2014;45(12):3535-3542.
53. Frontera JA, Fernandez A, Schmidt JM, et al. Impact of nosocomial infectious complications after subarachnoid hemorrhage. *Neurosurgery.* 2008; 62(1):80-87, discussion 87.
54. Bogossian EG, Attanasio L, Creteur J, Grimaldi D, Schiud S, Taccone FS. The impact of extracerebral infection after subarachnoid hemorrhage: a single-center cohort study. *World Neurosurg.* 2020;144:e883-e897.
55. Al-Khaled M, Awwad S, Brüning T. Nontraumatic spontaneous intracerebral hemorrhage: baseline characteristics and early outcomes. *Brain Behav.* 2020;10(1):e01512.
56. Moulis G, Palmaro A, Sailler L, Lapeyre-Mestre M. Corticosteroid risk function of severe infection in primary immune thrombocytopenia adults. A nationwide nested case-control study. *PLoS One.* 2015;10(11):e0142217.
57. Moulis G, Lapeyre-Mestre M, Palmaro A, Sailler L. Infections in non-splenectomized persistent or chronic primary immune thrombocytopenia adults: risk factors and vaccination effect. *J Thromb Haemost.* 2017;15(4):785-791.
58. Wu YJ, Hou M, Liu HX, et al. A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data [published correction appears in *Blood Adv.* 2021;5(2):365]. *Blood Adv.* 2020;4(22):5846-5857.
59. Goeijenbier M, van Wissen M, van de Weg C, et al. Review: viral infections and mechanisms of thrombosis and bleeding. *J Med Virol.* 2012; 84(10):1680-1696.
60. Keller TT, Mairuhu AT, de Kruif MD, et al. Infections and endothelial cells. *Cardiovasc Res.* 2003;60(1):40-48.
61. Salottolo K, Levy AS, Slone DS, Mains CW, Bar-Or D. The effect of age on Glasgow Coma Scale score in patients with traumatic brain injury. *JAMA Surg.* 2014;149(7):727-734.
62. Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. *Stroke.* 2003; 34(8):2060-2065.
63. Murthy SB, Moradiya Y, Shah J, et al. Nosocomial infections and outcomes after intracerebral hemorrhage: a population-based study. *Neurocrit Care.* 2016;25(2):178-184.
64. Moussouttas M, Malhotra R, Fernandez L, et al. Role of antiplatelet agents in hematoma expansion during the acute period of intracerebral hemorrhage. *Neurocrit Care.* 2010;12(1):24-29.
65. Hagii J, Tomita H, Metoki N, et al. Characteristics of intracerebral hemorrhage during rivaroxaban treatment: comparison with those during warfarin. *Stroke.* 2014;45(9):2805-2807.
66. Flores A, Buchanan GR. Occult hemorrhage in children with severe ITP. *Am J Hematol.* 2016;91(3):287-290.
67. Cooper N, Morrison MA, Vladescu C, et al. Identification of occult cerebral microbleeds in adults with immune thrombocytopenia. *Blood.* 2020; 136(25):2875-2880.